This Week in Rheumatology — Sep 24, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning vasculitis risk stratification and early biologic therapy, the steroid-sparing treat-to-target agenda in lupus, and remission, tapering and refractory disease in inflammatory arthritis, with a diagnostic imaging study and a cardiology crossover along the way. Let's dive in.

We'll start with vasculitis, where two papers approach the same underlying problem — how to personalise intensity of therapy — from opposite ends. In the Annals of the Rheumatic Diseases, Junek and colleagues used the PEXIVAS trial population to derive a model estimating the risk of a first relapse within two years of achieving remission in ANCA-associated vasculitis [1]. Among 649 participants, all of whom had severe disease with either badly impaired kidney function or diffuse alveolar haemorrhage, 100 patients relapsed within two years. The final model draws on sex, whether induction was with oral cyclophosphamide or rituximab, ANCA subtype, non-haemorrhagic respiratory or mucous membrane and eye involvement at presentation, and kidney function at remission. Discrimination was moderate — a concordance statistic of about 0.71, which is useful for stratifying groups rather than adjudicating an individual — and calibration was close to ideal. The authors are explicit that external validation is still needed, and the derivation population is severe disease only, so this is a tool for research and shared discussion rather than a guideline-endorsed instrument. On the treatment side, Rheumatology published a retrospective multicentre Japanese cohort from Maruyama and colleagues asking whether starting mepolizumab early, within three months of remission induction, changes the course of eosinophilic granulomatosis with polyangiitis [3]. Sixty-four patients, only 16 of them in the early group. Clinical remission at one year — meaning no vasculitis activity on four milligrams of prednisolone or less — was reached by roughly seven in ten early-treated patients versus under three in ten treated conventionally, and by two years every evaluable early-treated patient was in remission. Longitudinal damage scores were modestly lower too. The direction is consistent and biologically plausible, but with 16 exposed patients and a retrospective design, confounding by indication is the obvious concern, and this is hypothesis-generating rather than practice-defining.

Turning to lupus, where three papers converge on glucocorticoids as the central modifiable exposure. In RMD Open, Parodis and colleagues asked whether tightening the steroid ceiling inside the Lupus Low Disease Activity State — from seven and a half milligrams of prednisone down to five, in line with current guidance — strengthens the link with protection against organ damage [4]. Across 332 patients, more time spent in the stricter state was robustly associated with less damage accrual, cutting the damage rate by roughly 40 percent after adjustment. But here is the honest finding: the stricter definition looked numerically better only in unadjusted analyses, and that apparent advantage did not survive multivariable adjustment. Both definitions performed similarly. So the paper supports the lower threshold as a legitimate, guideline-aligned target, while leaving its incremental value over the conventional definition unproven. That sits alongside a review in Rheumatology from Morand and colleagues tracing the decade-long development of treat-to-target in lupus, and the way more effective therapies have raised attainment of these targets while lowering corticosteroid burden [5]. The third lupus paper, also in RMD Open, gives the clearest picture yet of why steroid burden matters early. Nikoloudaki and colleagues followed an inception cohort of 311 patients within two years of diagnosis, tracking 140 comorbidities over five years [10]. Close to half of the patients — 45 percent — followed a fast comorbidity accrual trajectory, separating into a metabolic-psychiatric phenotype, a cardiopulmonary-musculoskeletal phenotype, and a broader non-patterned group. Fast accruers were less likely to attain low disease activity or remission and accumulated between roughly two and three times the organ damage and safety events of slow accruers. Two features of the first 24 months independently predicted that fast trajectory: spending at least a fifth of the time in severe flare, which roughly doubled the odds, and cumulative glucocorticoid exposure. This is observational and single-cohort, so causality is not settled, but it puts the treat-to-target and steroid-ceiling literature into sharper relief — the comorbidity divergence appears to begin in the first two years, not late.

Moving to inflammatory arthritis, where three papers address remission, tapering and refractoriness. Arthritis and Rheumatology published the ten-year follow-up of the CRESPA trial from Damen and colleagues, in which patients with very early peripheral spondyloarthritis — symptom duration of twelve weeks or less — were randomised to golimumab or placebo for remission induction [6]. Of 49 patients re-evaluated at a mean of ten and a half years, just over eight in ten were in clinical remission, and about one in three were in longstanding drug-free remission. The striking signal is in the non-psoriatic subgroup: nearly half of patients with peripheral spondyloarthritis without psoriasis remained drug-free, and absence of psoriasis at baseline was the only meaningful predictor, raising the odds of drug-free remission around ninefold. This is a descriptive, uncontrolled long-term follow-up of a small cohort with attrition, so it cannot prove that early intensive treatment caused the durable remission — but it is among the strongest available evidence that a window of opportunity exists in peripheral spondyloarthritis. On tapering in rheumatoid arthritis, RMD Open carried work from Blanco and colleagues using serum proteomics and autoantibody profiling in patients from the OPTIBIO trial who were in sustained remission [8]. Flare occurred in roughly 46 percent of patients randomised to biologic optimisation versus about 31 percent of controls. Two markers held up in the full cohort of 194 — the protein VSIG4 and anti-interferon-gamma autoantibodies — and adding them to a clinical model raised discrimination from about 0.67 to 0.76, with better performance still in those with prolonged remission. The authors state plainly that external validation is required before any clinical use. And on the other end of the disease spectrum, also in RMD Open, Van Mullem and colleagues interrogated a twenty-year real-world cohort of 675 patients to ask whether the initial biologic choice shapes progression to difficult-to-treat rheumatoid arthritis [9]. Just under one in five patients met difficult-to-treat criteria. Neither starting with a TNF inhibitor versus another mechanism, nor cycling versus switching mechanism, was associated with that outcome. What was associated was glucocorticoid exposure, which roughly two-and-a-half-fold increased the hazard — echoing the lupus data — though in an observational design steroid use is very likely marking disease severity as much as causing harm.

Two further papers round out the week. In the Lancet Rheumatology, Våben and colleagues report the first properly designed diagnostic accuracy study of musculoskeletal ultrasound in suspected polymyalgia rheumatica, across two independent consecutive cohorts of glucocorticoid-naive patients in the Netherlands and Denmark, with clinical diagnosis at six or twelve months as the reference [2]. No single ultrasound finding was pathognomonic. At least one inflammatory lesion was highly sensitive at over ninety percent in both cohorts, while lesions in both the shoulder and hip girdles gave the best specificity, in the mid-eighties to low nineties. Overall discrimination was moderate, with areas under the curve near 0.77 in both cohorts, and crucially ultrasound separated polymyalgia rheumatica from non-inflammatory conditions far better than from other inflammatory rheumatic diseases — which is precisely the harder clinical question. Also in the Lancet Rheumatology, Plein and colleagues appraise the 2025 European Society of Cardiology myocarditis and pericarditis guidelines from a rheumatology perspective [7], arguing that because myopericardial involvement in systemic autoimmune rheumatic disease is usually subclinical and atypical, and because chronic inflammation degrades the accuracy of conventional biomarkers and advanced imaging in this group, the generic diagnostic pathways transfer poorly and disease-specific, jointly developed pathways are still missing.

If you only have time for one paper this week, make it the ten-year CRESPA follow-up in Arthritis and Rheumatology [6]. It reopens, with the longest horizon yet, the question of whether very early intensive treatment in peripheral spondyloarthritis can buy durable drug-free remission — and it suggests the answer depends heavily on whether psoriasis is present.

Here is what this week's evidence adds up to in Rheumatology. First, glucocorticoid exposure surfaces independently in three separate cohorts — as a predictor of fast comorbidity accrual in early lupus, as a correlate of progression to difficult-to-treat rheumatoid arthritis, and as the very parameter being tightened inside the low disease activity definition — though all of this is observational and steroid use inevitably tracks with disease severity. Second, risk stratification tools are maturing but none are ready for the clinic: the ANCA-associated vasculitis relapse model and the rheumatoid arthritis tapering biomarker signature both show moderate discrimination and both explicitly await external validation. Third, the case for a window of opportunity is strongest in peripheral spondyloarthritis, where a third of patients from a randomised induction trial remained drug-free at a decade, but this is descriptive long-term follow-up of a small cohort. Fourth, in polymyalgia rheumatica, ultrasound looks best used to rule out inflammatory disease rather than to confirm the diagnosis, since it struggles to distinguish polymyalgia rheumatica from other inflammatory conditions. And finally, the mepolizumab and myopericarditis papers both mark areas where practice is running ahead of formal guidance, and where the authors themselves call for better evidence and joint pathways.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.